tiprankstipranks

Vivoryon Therapeutics Unveils Promising R&D Progress in Kidney Disease Treatment

Story Highlights
  • Vivoryon Therapeutics is advancing varoglutamstat, which improves kidney function in DKD.
  • The company plans a Phase 2b study and introduces VY2149, focusing on kidney disease.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Vivoryon Therapeutics Unveils Promising R&D Progress in Kidney Disease Treatment

Vivoryon Therapeutics AG ( (GB:0R3M) ) has shared an announcement.

Vivoryon Therapeutics announced significant progress in its R&D efforts for varoglutamstat, a compound showing promising results in improving kidney function in diabetic kidney disease (DKD). The company’s virtual update highlighted the potential market positioning of varoglutamstat, alongside the introduction of a new development compound, VY2149, and plans for a Phase 2b study. By leveraging a novel mechanism of action targeting inflammation and fibrosis, Vivoryon is positioning itself as a leader in kidney disease treatment, although it has decided to discontinue varoglutamstat’s use in Alzheimer’s disease.

More about Vivoryon Therapeutics AG

Vivoryon Therapeutics AG is a clinical stage company engaged in the discovery and development of small molecule medicines. The company is focused on modulating the activity and stability of pathologically altered proteins, with a market focus on kidney disease treatments.

YTD Price Performance: 4.27%

Average Trading Volume: 3,502

Technical Sentiment Consensus Rating: Buy

Current Market Cap: €54.22M

See more data about 0R3M stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App